Cassava Sciences Inc (SAVA)

Apr 09, 2025

SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

SAVA Stock Plummets to 52-Week Low at $1.16 Amid Market Struggles - Investing.com Australia

Apr 09, 2025

Apr 07, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire

Apr 07, 2025

Apr 05, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Stockholders to Connect - ACCESS Newswire

Apr 05, 2025

Apr 02, 2025

SAVA stock touches 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 02, 2025

SAVA stock touches 52-week low at $1.34 amid market challenges - Investing.com Australia

Apr 02, 2025

Apr 02, 2025

SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 02, 2025

Apr 01, 2025

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround - Yahoo Finance

Apr 01, 2025

Mar 31, 2025

After Two Phase 3 Trial Fails, Cassava Sciences Gives Up On Alzheimer’s Drugs - Being Patient

Mar 31, 2025

Mar 31, 2025

Is the Future Bleak for SAVA Stock Following Another Setback? - Nasdaq

Mar 31, 2025

Mar 31, 2025

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - MSN

Mar 31, 2025

Mar 31, 2025

Cassava Sciences Stock Drops Over 30% After Alzheimer’s Drug Fails Study – But Retail Remains Hopeful - MSN

Mar 31, 2025

Mar 30, 2025

Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus - MSN

Mar 30, 2025

Mar 26, 2025

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer’s drug By Reuters - Investing.com

Mar 26, 2025

Mar 26, 2025

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study - MSN

Mar 26, 2025

Mar 26, 2025

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More - Zacks Investment Research

Mar 26, 2025

Mar 26, 2025

Cassava ends Alzheimer’s program after simufilam fails again - The Pharma Letter

Mar 26, 2025

Mar 26, 2025

Cassava ends simufilam Alzheimer’s programme after second Phase III failure - Yahoo Finance

Mar 26, 2025

Mar 26, 2025

Cassava Sciences Reports Topline Phase 3 Refocus-Alz Data - MarketScreener

Mar 26, 2025

Mar 25, 2025

Rodman & Renshaw maintains Sell rating on Cassava Sciences stock By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

SAVA stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Sector Update: Health Care Stocks Fall Late Afternoon - TradingView

Mar 25, 2025

Mar 25, 2025

Sector Update: Health Care - MarketScreener

Mar 25, 2025

Mar 25, 2025

Rodman & Renshaw maintains Sell rating on Cassava Sciences stock - Investing.com India

Mar 25, 2025

Mar 25, 2025

Top Midday Decliners - MarketScreener

Mar 25, 2025

Mar 25, 2025

Cassava Sciences Stock: Alzheimer Drug Fails, Program Terminated - Sharewise

Mar 25, 2025

Mar 25, 2025

Cassava Drops 19% Pre-Market After Decision to End Alzheimer's Program - Yahoo Finance

Mar 25, 2025

Mar 25, 2025

Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam - BioSpace

Mar 25, 2025

Mar 25, 2025

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop - Benzinga

Mar 25, 2025

Mar 25, 2025

Cassava ends work on Alzheimer’s drug; Alumis gets $40M upfront from Kaken - Endpoints News

Mar 25, 2025

Mar 25, 2025

Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study - NewsBreak: Local News & Alerts

Mar 25, 2025

Mar 25, 2025

Cassava stock down as Alzheimer’s program ends (SAVA:NASDAQ) - Seeking Alpha

Mar 25, 2025

Mar 25, 2025

Cassava Sciences shuts down Alzheimer's programshares plummet - Marketscreener.com

Mar 25, 2025

Mar 25, 2025

SAVA stock touches 52-week low at $2.15 amid market challenges - Investing.com Australia

Mar 25, 2025

Mar 25, 2025

Cassava Sciences' Phase 3 Study of Simufilam Showed No Benefit for Alzheimer's Patients - MarketScreener

Mar 25, 2025

Mar 25, 2025

Cassava to discontinue development of Alzheimer’s disease drug - KFGO

Mar 25, 2025

Mar 25, 2025

Cassava Sciences ends Alzheimer’s treatment development after unsuccessful trials By Investing.com - Investing.com UK

Mar 25, 2025

Mar 25, 2025

Cassava Sciences stock tumbles after Alzheimer’s drug fails key study By Investing.com - Investing.com Canada

Mar 25, 2025

Mar 25, 2025

Cassava to discontinue development of Alzheimer's disease drug - MarketScreener

Mar 25, 2025